Category Archives: Healthcare

Finally an Answer for the National Opioid Crisis

An at home program for curing opioid addiction with extremely high cure rates is revealed.

Sylva, NC, USA — Dr. Winn Henderson has just released this week his 41st book entitled: “Freedom From Addiction 3” which offers a treatment program which can be accomplished at home to cure opioid addiction. If the addicted individual meets three simple criteria there is a 100% cure rate.

Dr. Winn Henderson is a retired physician with over 20 years of clinical experience. He is the author of 41 books including The Cure of Addiction, The Four Questions, Share Your Mission, The Deposition, The Secret to Happiness, The 12 Steps, and this book, Freedom From Addiction 3. For the last 20+ years, Dr. Henderson has been counseling both in person and by telephone clients from all over the world on issues of addiction and finding one’s purpose in life. He is the host of a 17-year long radio/internet talk show: “Freedom From Addiction/Share Your Mission.” His iTunes podcast: “Freedom From Addiction” can be heard 24/7 all over the world. The doctor is immediately available for national interviews.

Media Contact:
Winn Henderson, M.D.
Freedom From Addiction
828-508-7981
winn@winnhenderson.com
http://www.freedomfromaddictionii.com

Connect. Integrate. Become One.

International Day of Yoga 21 June

Alpharetta, Georgia, US, 2017-Jun-13 — /REAL TIME PRESS RELEASE/ — The Heartfulness Institute will mark the International Day of Yoga on 21 June with public events in various locations globally (www.heartfulness.org). The events will be held at the Institute’s meditation and retreat centres and also at other community venues in partnership with civil society and yoga organizations and Indian diplomatic missions.

Every year on 21 June the United Nations invites the global community to celebrate the life-enhancing practices of Yoga. In establishing the International Day of Yoga, the United Nations underscored the need for building better lifestyles, recognizing that Yoga provides a holistic approach to health and well-being. The UN also called for the wider dissemination of information about the benefits of practising Yoga.

On the International Day of Yoga, the Heartfulness community, led by its youth, will bring together hundreds of thousands of people with the theme ‘Connect. Integrate. Become One’, in Chennai, Singapore, Hyderabad, Paris, New York, London, Toronto, Sydney and in other major metropolitan centres, as well as in many smaller cities, towns and rural areas globally. The core practices of Heartfulness are self-development tools for a modern lifestyle and for people from all walks of life. They include relaxation, heart-based meditation, cleaning and inner connection. There is no dogma or prerequisite of any kind, and no financial requirement; only the willingness and interest to try the simple, effective Heartfulness practices.

Since the beginning of 2017, the Heartfulness Institute has been offering free masterclasses in meditation, led by its global guide, Kamlesh Patel, also known as Daaji. More than one million people around the world, including educational, business and professional groups, have experienced the free masterclasses that are available at http://en.heartfulness.org/masterclass/.

Heartfulness is an approach to the Raja Yoga system of meditation called Sahaj Marg, founded at the turn of the 20th century and formalized into an organization in 1945. More than seventy years later, ongoing Heartfulness meditation training can be found at 2,500 schools and colleges, and over 100,000 professionals are meditating in over 3,000 corporations, non-governmental and government organizations.

Heartfulness Centres, known as HeartSpots, exist in 130 countries, supported by thousands of certified volunteer trainers. There are over 5,000 HeartSpots and over 300 retreat centres around the world where thousands of people gather to meditate (http://www.heartfulness.org/).

About Kamlesh D. Patel
Known to many as Daaji, Kamlesh D. Patel is the fourth guide in the Heartfulness tradition of meditation. He is a prolific speaker and writer, and you can read his latest writings at http://www.daaji.org/.

About Heartfulness Institute
Heartfulness Institute is a non-profit organization that promotes well-being and self-development through meditation, research and training. The Institute offers programs for individuals, local communities, corporates, government departments and the armed services, schools and colleges, rural communities and civil society groups worldwide, supported by certified trainers who are volunteers and who offer their time and expertise in this social cause.

For more information 
Email: info@heartfulness.org
Toll free numbers:India: 1-800-103-7726USA: 1-844-879-4327
Social Media: Heartfulness Facebook | Twitter | Google+ | YouTube | LinkedIN | Instagram

Websites: www.heartfulness.org, www.daaji.org
Durga Nagarajan, 180 Westchester Way, Alpharetta,Georgia 30005

New All-Natural Supplement Proven to Help Prevent and Heal Liver Conditions

Highly-regarded company Kyotsujigyo Inc. recently introduced Yojyo Henshi Ko to markets outside of Japan, offering a natural-based liver supplement that is clinically proven to improve liver health.

Tokyo, Japan, June 3rd, 2017 — Highly-regarded company Kyotsujigyo Inc. recently introduced Yojyo Henshi Ko to markets outside of Japan, offering a natural-based liver supplement that is clinically proven to improve liver health.

Yojyo Henshi Ko, known as YHK, has a patented formula specifically geared toward being as natural as possible. The formula consists of the following powerful herbs: panax pseudo ginseng, euccommia ulmoides, licorice root and rhizoma polygonati. These ingredients are known in nature to have strong anti-oxidant and healing effects in the body. “Yojyo Henshi Ko is the liver therapy of nature,” said Kyotsujigyo Hong Kong Branch Manager James Ma. “Our company has more than 25 years of experience in inventing healing supplements, and YHK is one that is specifically designed for liver recovery.”

With more than 30 different clinical scientific studies conducted and many research papers published, YHK is the most advanced liver protection supplement currently available. The scientific-based supplement holds patents in the United States, Canada, Japan, Europe and China. “Our product is suitable for people with all kinds of liver problems and conditions, especially for those who have chronic liver problems,” Ma said.


Published research data collected by the U.S. National Library of Medicine (PubMed.gov) indicates that YHK can help treat and prevent NASH. NASH, Non-Alcoholic Steatohepatitis (a type of fatty liver disease), is becoming increasingly common for people who do not consume large amounts of alcohol. It is predicted to be the leading cause of liver transplants by the year 2020. This condition is caused by liver inflammation and damage due to the buildup of fat in the liver. The damage causes the liver to not work as well as it should. Additionally, NASH can cause scarring on the liver and lead to cirrhosis. Clinical data shows that YHK can strengthen and recover liver function and lower the ALT liver enzyme level.

Currently, there is no known medical treatment for NASH, which makes YHK a unique and viable option for people who suffer from liver problems. “When YHK is taken as directed, enzyme levels will lower and normalize,” said Ma, explaining YHK’s immediate results. “More than ninety percent of chronic liver disease patients saw liver improvement after 14 days of use.”

YHK has received a great deal of positive consumer feedback on its website. Customer reviews claim that the supplement does precisely what it guarantees to do, produces life-changing results, and improves health and liver function. Since it is composed of all-natural ingredients, YHK is safe to take with other medicines.

Professionally-recommended, YHK can strengthen and repair liver cells; recover and protect liver function; help the liver function properly; and prevent further damage—all with no health side effects. It is considered to be safe for long-term use.

Consumers can also experience the following benefits when taking YHK as suggested:

* Improved energy level
* Better appetite
* Improved sleep
* Improved skin
* Reduced side effects from other medications.
* Enhanced immune system
* Reduce risk of liver cancer

Kyotsujigyo was founded in the early 90’s by S.H. Sha, a Musashino University professor who specialized in health maintenance, anti-aging and disease prevention, and it is committed to helping people improve and maintain their health. The company has expertise in Japanese Kampo Medicine and many of its research work is listed in the U.S. National Library of Medicine. In addition, Kyotsujigyo is a member of the Massachusetts Institute of Technology Liaison Program.

For more information about Kyotsujigyo or YHK, visit www.kyotsujigyo.net or www.yhktherapy.com.

Press & Media Contact:
James Ma
Hong Kong Branch Manager
Kyotsujigyo
Tokyo, Japan
+852 6702 2602
mail@kyotsujigyo.net
http://www.yhktherapy.com

Algae Dynamics Corp Announces Research Agreement With University of Western Ontario to Investigate the Use of Cannabis Derivatives for the Development of Novel Pharmacotherapies for Mental Health

Algae Dynamics announces a development agreement with Western University to do research on cannabis oil in the context of depression, post-traumatic stress disorder & schizophrenia.

Toronto, Canada — ALGAE DYNAMICS CORP (OTCQB: ADYNF) (the “Company”), a development stage company focused on the development of unique health products and pharmaceuticals utilizing cannabis and algae oils, today announced a research and product development agreement with Western University to perform research on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia. This is the second of the recently announced research agreements with Canadian universities involving cannabis oil research. This announcement brings Algae Dynamics total university research contributions to $1.6 million for both programs.

This announcement follows the Company’s previously announced new strategic initiative to explore the extraction of oils from other botanicals, most notably cannabis, and to seek product development and formulation opportunities that combine the benefits of algae and cannabis oils. This research agreement will directly support this initiative and will “focus on translational pharmaceutical research, with a specific focus on identifying how specific phytochemical compounds found in cannabis, including delta-9-tetrahydrocannbinol (THC), cannabidiol (CBD), cannabinoid-derived terpenoids and other potential phytochemical derivatives of cannabis may serve as novel pharmacological treatments for symptoms associated with depression, post-traumatic stress disorder, anxiety and schizophrenia.”

Paul Ramsay, Chairman and President of the Company said, “With this research agreement, we are building upon the previously announced strategic initiative into the use of extracts from cannabis oil, in conjunction with algae oil, to develop unique health products and formulations. In our previous press release, we outlined a three-part approach, the first being Research and Development work with Canadian universities. This is the second of such research agreements relating to the use of botanical extracts including cannabinoids that we expect to employ”.

The investigator leading the research is Dr. Steven Laviolette, a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University. Dr. Laviolette is a leader in the study of cannabinoids in mental health. Dr. Laviolette’s research team has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette’s primary research focus is in characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette’s team has been published in the top neuroscience and psychiatry journals in the world. His full profile may be seen on the Western University, website http://www.uwo.ca:

http://www.schulich.uwo.ca/anatomy/people/bios/faculty/laviolette_steve.html

The Company’s contribution to the four-year Sponsored Research Agreement, which commences April 1, 2017 and terminates March 30, 2021, is C$250,000 per year. The Company believes, from past experience, that it will be able to leverage the research expenditures with matching scientific grants pursuant to programs of various branches of government. The Company will be responsible for the filing of patents relating to this research and will own such patents if and when issued. The Company has agreed to make payments to the University upon filing of each patent, when each patent is issued, after first commercial sale and when gross sales reach C$1,000,000. There are no ongoing royalty payments, relating to the use of the patents. The workplan may be extended and modified to achieve best outcomes which may include 1) delegating specific research areas of research work that require additional technologies to appropriate providers; and 2) engaging research collaborators to extend the research into additional areas of benefit to the Company.

The Company’s core product development strategy has been the production of high volume specific algae species and extraction of Essential Fatty Acids (EFAs) which is the foundation of the endocannabinoid system (ECS). The ECS is a group of endogenous cannabinoid receptors located in the mammalian brain and throughout the central and peripheral nervous systems, consisting of neuromodulatory lipids and their receptors. The extracted algae Omega 3 oil with high concentrations of DHA is used as a health supplement product. In light of the potential synergies, the Company has developed its strategy which is aimed at developing new products and formulations that combine the health benefits of algae and cannabis oils.

As reported earlier, the Company is continuing to seek opportunities to partner with or take ownership in existing Access to Cannabis for Medical Purposes Regulations (ACMPR) licensed producers to allow for access to the marketplace.

About Algae Dynamics Corp
ADC is currently engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. This is an extension of our plan to commercialize our proprietary BioSilo® algae cultivation system for the high volume, low cost production of pure contaminant-free algae biomass which is high in Omega-3 fatty acids. We have engaged two Canadian universities to provide research into the use of extracts from cannabis oil, which we plan to use to develop products that combine the significant health benefits of Omega-3s derived from algae oil and extracts from cannabis oil. Our research is focusing on the use of cannabis oil in the context of cancer, and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health.

NOTE REGARDING FORWARD-LOOKING STATEMENTS
This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, use of proceeds and the development, costs and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

FOR MORE INFORMATION, PLEASE CONTACT:
Paul Ramsay
Phone: 289-997-6740
Email: ramsay(at)algaedynamics.com
http://www.algaedynamics.com

Monterey Peninsula Surgery Centers Launches Minimus Institute

MPSC extends its quality outpatient care nationally with Minimus Institute, a national referral center offering patient-focused surgical care in a concierge setting

Monterey, CA, March 03, 2017 — Monterey Peninsula Surgery Centers (MPSC), a highly respected surgical care provider and the largest locally-owned outpatient surgery organization in California, performs nearly 17,000 surgical procedures in 13 specialties annually. Every day more than 70 individuals and their families trust MPSC for their surgical care. MPSC’s esteemed team of surgeons, anesthesiologists, nurses and patient service providers have been delivering extraordinary care to the communities of Monterey, Salinas and Santa Cruz for over 35 years.

MPSC and its surgeons are recognized leaders in outpatient surgical care as measured by the high demand for its services, extremely low infection rates, 99% patient-satisfaction scores and affordable, transparent pricing. If MPSC was a hospital, it would rank No. 4 in the state in the number of outpatient surgeries performed annually.

Although the majority of MPSC’s patients reside in Northern and Central California, in the last five years, MPSC has attracted patients from 47 states and 10 countries seeking the most advanced surgical care.

Now, through Minimus Institute, which launched November 2016, MPSC is extending its services to patients living outside the Monterey, Santa Cruz and Salinas areas. Through Minimus Institute, MPSC will meet the unique pre and post-operative needs of patients traveling for surgery, including facilitating the surgeon-patient relationship, arranging physician consultations and booking travel accommodations, to ensure patients receive a stress-free experience. Since its launch last year, Minimus Institute has served patients from Oregon, Alaska and throughout California.

Minimus is a national surgery referral center that offers access to world-class surgeons and arms patients with real-time data on outcomes, infection rates, patient satisfaction scores and transparent pricing, all in a concierge setting. Minimus Institute strives to empower patients to make the most informed decisions about their care and guide them through their surgical experience.

Minimus Institute will begin with spinal surgery, but will expand to include orthopedic surgery, general surgery, gynecologic surgery and many other specialties.

“Patients can visit our website at MinimusInstitute.com to view up-front, all-inclusive pricing, patient satisfaction scores and infection rates to help them make an informed decision regarding their surgery options,” said Thomas D. Wilson, Managing Partner and CEO of MPSC and Minimus Institute. “Minimus provides patients an outstanding surgical experience with great value as measured by an optimum combination of quality, service and price. Because surgery is all we do, our hallmarks are efficiency, clarity and excellence. Our goal is to deliver surgery a better way. We strive to be pioneers in arming our patients with knowledge and we want to enable patients to make well-informed decisions.”

By leveraging the organization’s high-quality care and excellent patient experience with transparent pricing and outcomes, Minimus seeks to demystify the patient/surgery/doctor interaction.

Minimus‘ prime objective is to become recognized as a national destination surgery center or “beacon” for patients, insurance companies and self-insured groups seeking the most advanced and least invasive outpatient surgery in a setting featuring transparency, value and great outcomes. Patients can also access up-front, all-inclusive surgical pricing at http://minimusinstitute.com/procedures/.

About Minimus Institute:

Minimus Institute is a national state-of-the-art surgical institute located in a beautiful setting on California’s Central Coast, providing patients access to world-class surgeons and exceptional value. Offering transparent pricing and clear, comprehensive outcome information and patient-satisfaction scores, Minimus demystifies the surgical-care experience allowing patients to make the most informed decisions about their care. To learn more go to http://minimusinstitute.com/.

About Monterey Peninsula Surgery Centers (MPSC):

MPSC and its surgeons are recognized leaders in outpatient surgical care as measured by the high demand for its services, extremely low infection rates, 99% patient satisfaction scores and affordable, transparent pricing. It is known for performing complex surgery, including total joint replacements, major spine surgeries, hysterectomies, breast reconstruction and thyroidectomies in the outpatient setting. In excess of 31,500 surgical procedures across 13 specialties are performed annually at MPSC by its 190 physicians on staff.

High Resolution Photos Available: https://www.dropbox.com/sh/zo7s0a27obvtu3x/AACyJlJ5-2eFvdzSOg4awhUwa?dl=0

Contact:

Marci Bracco Cain

Chatterbox PR

Salinas, CA 93901

(831) 747-7455

http://minimusinstitute.com/

San Joaquin Valley Residents Can Now Take Advantage of Monterey, California-Based Minimus Institute’s Patient-Focused Surgical Care, World-Class Surgeons, Innovative Transparent Pricing and Outcome Reporting System, offered in a Concierge Setting

Minimus Institute, a Monterey, California-based national referral center offering state-of-the-art outpatient surgery to patients and self-insured groups throughout the country

Monterey, CA, March 02, 2017 — Minimus Institute, a Monterey, California-based national referral center offering state-of-the-art outpatient surgery to patients and self-insured groups throughout the country, is now taking patients from San Joaquin County including Fresno, Tulare, SLO, Madera, Merced, Mariposa and Stanislaus and is the first surgery center to offer county residents transparent pricing on its website http://minimusinstitute.com/pricing/.

With Minimus, San Joaquin County residents can travel to the beautiful coastal city of Monterey and receive nationally renowned patient-focused surgical care in a concierge setting, featuring world-class surgeons and an innovative transparent pricing and outcome reporting system.

Although the majority of their patients reside in Northern and Central California, in the last five years, Monterey Peninsula Surgery Centers (home of Minimus Institute), has become a national center, attracting patients from 47 states and 10 countries seeking the most advanced minimally invasive surgery.

“Patients can visit our website at MinimusInstute.com to view prices, patient satisfaction scores and infection rates to help them make an informed decision regarding their surgery options,” said Thomas D. Wilson, Managing Partner and CEO of Minimus Institute/MPSC. “Minimus provides patients an outstanding surgical experience with great value as measured by an optimum combination of quality, service and price. Because surgery is all we do, our hallmarks are efficiency, clarity and excellence. Our goal is to deliver surgery a better way. We strive to be pioneers in arming our patients with knowledge and we want to enable patients to make well-informed decisions.”

By leveraging the organization’s high-quality care, excellent patient experience combined with transparent pricing and outcomes, Minimus seeks to demystify the patient/surgery/doctor interaction.

Minimus’ prime objective is to become recognized as a national destination surgery center, or “beacon,” for patients, insurance companies and self-insured groups seeking the most advanced and least invasive outpatient surgery in a setting featuring transparency, value and great outcomes.

At Minimus, surgical care is provided at one of Monterey Peninsula Surgical Center’s locations around Monterey Bay. MPSC is the largest locally-owned outpatient healthcare facility in California, performing nearly 17,000 surgical cases annually. Every day more than 70 individuals and their families trust MPSC for their care. And, their esteemed team of surgeons and staff have been supporting patients for more than 35 years.

With Minimus, distance is not an obstacle to keep patients from the surgery they deserve. It is surgery and care worth traveling for.

Minimus Institute:

Minimus Institute is a national state-of-the-art surgical institute located in a beautiful setting on California’s Central Coast, providing patients access to world-class surgeons and exceptional value. Offering transparent pricing and clear, comprehensive outcome information and patient-satisfaction scores, Minimus demystifies the surgical-care experience allowing patients to make the most informed decisions about their care. To learn more go to http://minimusinstitute.com/.

Background on Monterey Peninsula Surgery Centers:

Monterey Peninsula Surgery Centers (MPSC) and its surgeons are recognized leaders in outpatient surgical care as measured by the high demand for its services, extremely low infection rates, 99% patient satisfaction scores and affordable, transparent pricing.

MPSC is known for performing complex surgery, including total joint replacements, major spine surgeries, hysterectomies, breast reconstruction and thyroidectomies in the outpatient setting. In excess of 31,500 surgical procedures in 13 specialties are performed annually at MPSC by its 190 physicians on staff.

Contact:

Marci Bracco Cain

Chatterbox PR

Salinas, CA 93901

(831) 747-7455

http://minimusinstitute.com/

Alaskan Residents Can Now Take Advantage of Monterey, California-Based Minimus Institute’s Patient-Focused Surgical Care, World-Class Surgeons, Innovative Transparent Pricing and Outcome Reporting System in a Concierge Setting

Minimus Institute, a Monterey, California-based national referral center offering state-of-the-art outpatient surgery to patients and self-insured groups throughout the country

Monterey, CA, March 02, 2017 — Minimus Institute, a Monterey, California-based national referral center offering state-of-the-art outpatient surgery to patients and self-insured groups throughout the country, is now taking patients from Alaska and is the first surgery center to offer Alaska residents transparent pricing on its website http://minimusinstitute.com/pricing/.

With Minimus, Alaskans can fly to the beautiful coastal city of Monterey and receive nationally renowned patient-focused surgical care in a concierge setting, featuring world-class surgeons and an innovative transparent pricing and outcome reporting system.

Although the majority of their patients reside in Northern and Central California, in the last five years, Monterey Peninsula Surgery Centers (home of Minimus Institute), has become a national center attracting patients from 47 states and 10 countries seeking the most advanced minimally invasive surgery.

“Patients can visit our website at MinimusInstute.com to view prices, patient satisfaction scores and infection rates to help them make an informed decision regarding their surgery options,” said Thomas D. Wilson, Managing Partner and CEO of Minimus Institute. “Minimus provides patients an outstanding surgical experience with great value as measured by an optimum combination of quality, service and price. Because surgery is all we do, our hallmarks are efficiency, clarity and excellence. Our goal is to deliver surgery a better way. We strive to be pioneers in arming our patients with knowledge and we want to enable patients to make well-informed decisions.”

By leveraging the organization’s high-quality care, excellent patient experience combined with transparent pricing and outcomes, Minimus seeks to demystify the patient/surgery/doctor interaction.

Minimus’ prime objective is to become recognized as a national destination surgery center, or “beacon,” for patients, insurance companies and self-insured groups seeking the most advanced and least invasive outpatient surgery in a setting featuring transparency, value and great outcomes.

At Minimus, surgical care is provided at one of Monterey Peninsula Surgical Centers’ locations around Monterey Bay. MPSC is the largest locally-owned outpatient healthcare facility in California, performing nearly 17,000 surgical cases annually. Every day more than 70 individuals and their families trust MPSC for their care. And, their esteemed team of surgeons and staff have been supporting patients for more than 35 years.

With Minimus, distance is not an obstacle to keep patients from the surgery they deserve. It is surgery and care worth traveling for.

Minimus Institute:

Minimus Institute is a national state-of-the-art surgical institute located in a beautiful setting on California’s Central Coast, providing patients access to world-class surgeons and exceptional value. Offering transparent pricing and clear, comprehensive outcome information and patient-satisfaction scores, Minimus demystifies the surgical-care experience allowing patients to make the most informed decisions about their care. To learn more go to http://minimusinstitute.com/.

Background on Monterey Peninsula Surgery Centers:

Monterey Peninsula Surgery Centers (MPSC) and its surgeons are recognized leaders in outpatient surgical care as measured by the high demand for its services, extremely low infection rates, 99% patient satisfaction scores and affordable, transparent pricing.

MPSC is known for performing complex surgery, including total joint replacements, major spine surgeries, hysterectomies, breast reconstruction and thyroidectomies in the outpatient setting. In excess of 31,500 surgical procedures in 13 specialties are performed annually at MPSC by its 190 physicians on staff.

High Resolution Photos Available: https://www.dropbox.com/sh/zo7s0a27obvtu3x/AACyJlJ5-2eFvdzSOg4awhUwa?dl=0

Contact:

Marci Bracco Cain

Chatterbox PR

Salinas, CA 93901

(831) 747-7455

http://minimusinstitute.com/

Monaghan’s Drug-Free Aerobika® Device Helps Reduce the Real-World Impact of Exacerbations in Chronic Obstructive Pulmonary Disease

This study provides the first real-world evidence for the benefits of using the Aerobika® device in reducing exacerbation-related emergency department visits and hospital readmissions.

Syracuse, NY, USA — Monaghan Medical Corporation (MMC) (http://www.monaghanmed.com), today announced the publication of a study in Pulmonary Therapy showing that treatment with Monaghan’s Aerobika® device can significantly reduce the recurrence of exacerbations of chronic obstructive pulmonary disease (COPD) in the crucial 30-day period following hospitalization or emergency room visits.(1) The study also showed that per-patient cost of exacerbations was significantly lower in the group using the Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device. This study provides the first real-world evidence for the benefits of using the Aerobika® device in reducing exacerbation-related emergency department visits and hospital readmissions.

COPD is a major (and growing) source of morbidity, mortality and healthcare utilization, with hospitalization for acute exacerbations being the biggest cost driver. Once a patient experiences an exacerbation, the risk of further exacerbation is increased two- to four-fold(2), and many patients experience two or three exacerbations every year.(3-5) As many as one in five patients discharged from hospital following an exacerbation are re-admitted within 30 days.(6)

This retrospective study analyzed hospital database records for 810 COPD Chronic Bronchitis patients who were hospitalized or visited the emergency room, and showed significantly fewer patients given the Aerobika® device experienced moderate-to-severe exacerbations or severe exacerbations compared with matched controls within the critical 30-day follow-up period. The study also showed a statistically significant savings in exacerbation-related costs in the Aerobika® device group compared with the control group for moderate-to-severe and severe exacerbations. The Aerobika® device was given in addition to the patients’ regular COPD treatments.

“This is the first study to evaluate the benefits of any OPEP in a real-world setting. It provides encouraging evidence that the Aerobika® device can help reduce recurrence of exacerbations in high-risk patients over the crucial early 30-day period,” noted Dr. Michael Bauer, Pulmonary Physician, Cooperstown, New York.

Dominic Coppolo, MBA, RRT, FAARC, Vice President Clinical Strategy and Development at Monaghan Medical, explained how the Aerobika® device may provide these benefits: “During an exacerbation, airways are compromised by (among other factors) inflammation and mucus build-up. This can continue to disrupt ventilation mechanics and lung function after the event, and lead to prolonged respiratory impairment. The Aerobika® device, with its proprietary mechanism of action, helps stent open and clear excess mucus from the upper airways, and may also aid drug deposition, providing a potential mechanism of protection from exacerbations.”

The internationally-recognized GOLD guidelines(7) for COPD treatment stress the importance of exacerbation management, stating that a major treatment goal is to ‘minimize the negative impact of the current exacerbation and to prevent subsequent events.’ A recent analysis(2) predicts that the absolute number of COPD cases could increase by between 150% and 220% in the period from 2010 to 2030, with the burden of inpatient care (total annual inpatient days) growing by around 185%. This further underlines this need to address the burden of COPD exacerbations.

About the Aerobika® device study
A retrospective cohort study utilizing patient data from the U.S. hospital Charge Detail Master (CDM) claims database (data selection period between 1 September 2013 and 31 August 2015). This real-word study involved 810 COPD patients with a diagnosis of chronic bronchitis, 405 receiving treatment with the Aerobika® device and 405 matched controls, (propensity matched to reduce bias and mimic randomization). The data showed significantly fewer patients given the Aerobika® device experienced moderate-to-severe exacerbations (18.5% vs 25.7%, p=0.014) or severe exacerbations (13.5% vs 19.0%; p < 0.046) compared with matched controls over the 30-day follow-up period, with consequent reductions in costs.

About the Aerobika® Device
The Aerobika® device is hand-held, robust, easy-to-use, and drug-free with a proprietary mode of action. When the patient exhales through the device, intermittent resistance creates a unique pressure-oscillation dynamic, which expands the airways, helps expel the mucus to the upper airways where it can be coughed out, and may also aid in improved drug deposition. The Aerobika® device is designed to function independent of angle of use or flow rate, and allows for a direct aerosol pathway for patients using a nebulizer for medication delivery. The Aerobika® device has been shown to significantly improve forced vital capacity (FVC), 6-min walk distance (6MWD), and St. George's Respiratory Questionnaire (SGRQ) score in COPD patients.(8) The Aerobika® device is available in the U.S. from Monaghan Medical Corporation, and in Canada, Mexico, and select European countries including the UK and Germany through Trudell Medical International. (http://www.monaghanmed.com/Aerobika-OPEP)

About Monaghan Medical Corporation (MMC, USA)
MMC offers leading aerosol drug delivery devices and respiratory management products including AeroEclipse® II BAN, AeroChamber Plus® aVHC and the Aerobika® device exclusively in the United States. MMC’s strength lies in product development around core capabilities in mechanical design complimented by collaboration with a state-of-the-art aerosol research laboratory. MMC focuses on developing cost-efficient, outcome-based solutions for its customers. (http://www.monaghanmed.com)

References:

1. Burudpakdee C et al. Pulm Ther 2017 DOI 10.1007/s41030-017-0027-5. Pub online 6 February 2017.

2. Khakban A, et al. Am J Respir Crit Care Med 2017 Feb 1;195(3):287-291.

3. Balter MS, et al. Can Respir J 2003; 10 (Suppl B):3B-32B.

4. Perera PN, et al. COPD J Chron Obst Pulm Dis 2012;9(2):131-41.

5. Puhan MA, et al. Respir Res 2005;6 (1): 1.

6. Shah T, et al. Chest. 2016 Oct;150(4):916-926.

7. The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: http://goldcopd.org (Last accessed 2 Feb 2017).

8. Svenningsen S, et al. COPD 2016;13(1):66-74.

For clinical inquiries, please contact:
Dominic P. Coppolo, MBA, RRT, FAARC
Vice President of Clinical Strategy and Development
Monaghan Medical Corporation
1-800-343-9071

Protecting Patients and Preventing Drug Diversion: Senator Alloway, Representative Nesbit Introduce Pennsylvania Orthopaedic Society’s E-prescribing Legislation

Today, State Senator Richard Alloway and State Representative Tedd Nesbit announced the introduction of legislation to mandate the electronic prescribing of opioid medications.

Harrisburg, PA, February 06, 2017 – Today, State Senator Richard Alloway and State Representative Tedd Nesbit announced the introduction of legislation to mandate the electronic prescribing of opioid medications. The bill is an initiative of the Pennsylvania Orthopaedic Society (POS). Society President Patrick Smith, MD, as well as POS board members, joined legislators in the Main Capitol Rotunda to announce the legislation.

“We stand with Senator Alloway and Representative Nesbit to advance a solution that works in the fight against opioid addiction,” Smith said. “Opioid e-prescribing will absolutely reduce drug diversion due to written prescriptions being lost, stolen or sold. It just plain makes sense in 2017. We thank Senator Alloway, Representative Nesbit and all the other legislators who have joined us today to gain this vital patient protection measure.”

Currently, Pennsylvania law requires opioid prescriptions to be handwritten. A vestige of the pre-internet era, this statute has not been updated since the 1990s. Although physicians may prescribe all other medicine by electronic means, opioids must still be prescribed by handwritten prescriptions. The Alloway and Nesbit bills (SB 299 and HB 353) ?will bring opioid prescribing into the 21st Century.

“Patients and physicians throughout the Commonwealth can feel more secure now that legislative action is pending on opioid e-prescribing,” Smith said. “Paper scripts will no longer put our communities at risk of drug diversion and hamper patient care. We respectfully request the General Assembly to quickly move this solution that works.”

In addition to reducing drug diversion, opioid e-prescribing will add to patient convenience. Like with other medications, opioid e-prescribing will reduce patient wait times in pharmacies. It will also increase patient security by eliminating the risk of opioid prescriptions being stolen.

“There are a multitude of reasons for the current opioid addiction crisis and the General Assembly took important steps last session to turn the tide against it. Opioid e-prescribing is a simple and effective solution and should be added to the arsenal of weapons available to physicians to combat the crisis,” Smith concluded.

Advocating for excellence in the practice of orthopaedic medicine, POS is a professional medical specialty organization representing more than 1000 orthopaedic surgeons across Pennsylvania. For more information on the importance of bone, joint and muscle health at every age, visit www.paorthosociety.org.

Contact:

Steven Infanti

PA Orthopaedic Society

Harrisburg, PA 17101

717-909-8901

justmehbg@earthlink.net

http://www.paorthosociety.org

New York’s Health Agency (NYSDOH) Cited in Iraq War’s Blowback

New York, NY, 2016-Dec-31 — /REAL TIME PRESS RELEASE/ — As the Iraq War’s official end on December 18, 2011 marks its fifth anniversary, many questions remain on its fallouts. New York’s French-American community is one of them, as it remembers its blacklisting when France opted out of attacking Iraq.

Choosing diplomatic pressure rather than “shock and awe” ignited fury for many in New York. The call for anti-French boycotts resonated in tabloids as pictures of New Yorkers spilling wines in gutters vied with accusations of an ally’s betrayal and cowardice. Information can be found by googling “New York’s French boycotts and Iraq,” and “Freedom fries.”

How effective were the boycotts? “Very much so, even devastating,” says French consulate’s official physician and mental health coordinator at the time, Gérard Sunnen, MD, “the French-American community of New York was stunned by their virulence. Why, many wondered, did they materialize only in New York, in striking contrast to the rest of the country?”

“Targeted were all manner of French-American businesses, from Air France to bakeries, as rosters of marked companies circulated widely. Earliest felled were restaurants, whose sales plummeted by as much as half. Like dominoes, they closed their doors, dismissing their workers. Called by many the “consulate’s darkest hour,” it went on for weeks, interminable months, and still resonates today.”

“As layoffs mounted,” Dr. Sunnen added, “so did their mental health consequences, from all manner of stress reactions to self-destructive depressions. And workers suddenly out of work could not find employment because no one would take them. The consulate’s social services department work load soared to levels never attained before.”

Faced with this onslaught, the New York State Department of Health (NYSDOH) was repeatedly contacted to lend the community its medical and mental health assistance. In addition, New York state and city top officials were insistently asked to add their voice to call off the boycotts. All appeals remained unanswered and, for reasons of non-assistance and abandonment of responsibility, this matter was eventually reported and filed in New York and Federal courts.

Dr. Sunnen, who also cites his experience as a Vietnam-era U.S. veteran, concludes, “history needs constant reckoning, otherwise it can remain a fable. These events are now brought to light so that long-term allies can better understand the meaning of their relationship.”

References:

Gérard Sunnen, MD: www.triroc.com/sunnen
Supreme Court, State of New York, No. 102194/2012
U.S. District Court, Southern District of NY 12 Civ. 3417
U.S. Court of Appeals, 2nd Circuit 13-465cv
U.S. Health and Human Services (HHS) 1:13-cv-1242
New York State Division of Human Rights (NYSDHR) No. 10181422
National Transportation Safety Board (NTSB) No. DCA96MA070

Contact-Details: Gerard Sunnen, MD